Fate Therapeutics announces FDA clearance of FT839 IND application
Fate Therapeutics announced that the FDA has cleared its investigational new drug, or IND, application for FT839, the company's next-generation, off-the-shelf CAR T-cell product candidate engineered to co-target CD19 and CD38. With IND clearance, the company plans to advance FT839 into a basket clinical trial intended